ABL90 Flex Plus Method Comparison Study_Adults

Sponsor
Radiometer Medical ApS (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06078956
Collaborator
(none)
360
1
2
10.7
33.7

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to validate performance claims for method comparison for the ABL90 FLEX PLUS for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in heparinized whole blood in a Point of Care (POC) setting.

Condition or Disease Intervention/Treatment Phase
  • Device: Measuring of analytes
N/A

Detailed Description

The main question it aims to answer is:

To quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all 15 parameters in heparinized arterial and venous patient whole blood in syringe measuring mode (S65, SP65) and heparinized capillary whole blood samples in capillary measuring mode (C65).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
360 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
ABL90 FLEX PLUS Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in Whole Blood in Adult Population.
Actual Study Start Date :
Feb 8, 2023
Anticipated Primary Completion Date :
Nov 30, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Investigational Device

Device: Measuring of analytes
Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.

Other: Predicate device

Device: Measuring of analytes
Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.

Outcome Measures

Primary Outcome Measures

  1. Slope, R^2 and bias at medical decision points [6-9 months]

    Primary Endpoints: Slope, R^2 and bias at medical decision points for each combination of modes and sample type, across sites

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The subject must be 18 years or older.

  • Informed consent collected from subject or from relative(s) able to understand information given and willing and able to voluntary give their consent to participate in this study.

  • The subject will provide blood samples from the existing Aand/ or V-lines, and/or from a finger stick.

  • Subject evaluated as suitable according to the protocol to enroll in the study by principal investigator or designee.

Exclusion Criteria:
  • Subject where sample collection is evaluated by principal investigator or designee to impose an unnecessary risk.

  • Subject, who is pregnant or breastfeeding.

  • Subject, who has an invalid written informed consent or has withdrawn consent.

  • Subject who has already provided successful measurements of arterial, venous and capillary samples, to cover both syringe modes and the capillary mode

  • Subjects taking medications listed in Appendix 1 with last dose within 72 hours, should be excluded due to interference.

  • Subjects with known infectious disease such as Hepatitis C and HIV (in order to ensure the operator safety).

Contacts and Locations

Locations

Site City State Country Postal Code
1 UC Davis Sacramento California United States 95817

Sponsors and Collaborators

  • Radiometer Medical ApS

Investigators

  • Study Director: Lisbet Bærentzen, PhD, Radiometer Medical ApS

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radiometer Medical ApS
ClinicalTrials.gov Identifier:
NCT06078956
Other Study ID Numbers:
  • DC-083659
First Posted:
Oct 12, 2023
Last Update Posted:
Oct 12, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Radiometer Medical ApS

Study Results

No Results Posted as of Oct 12, 2023